EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 10:30 a.m. ET. This presentation will highlight the company's commitment to developing innovative therapeutics for serious eye disorders. Investors can access a live webcast and an archived replay through the company website for 90 days post-event. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, utilizing its Durasert® technology for sustained drug delivery.
- None.
- None.
WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.
A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When will the fireside chat featuring EyePoint Pharmaceuticals' CEO take place?
How can I access the live webcast of the EyePoint Pharmaceuticals fireside chat?
What is EYP-1901, and what condition does it target?
How long will the replay of the EyePoint Pharmaceuticals fireside chat be available?
Which technology does EyePoint Pharmaceuticals use for drug delivery?
